Cargando…

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?

OBJECTIVE: Brand-generic scheme was implemented in Iran to improve the competition in the pharmaceutical market. In this study, we aim to assess if this policy had any positive effect on efficiency of Iranian pharmaceutical companies. METHODS: We used data envelopment analysis to evaluate the relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashemi-Meshkini, Amir, Varmaghani, Mehdi, Yousefi, Mehdi, Yaghoubifard, Saeed, Zekri, Hedieh-Sadat, Nikfar, Shekoufeh, Kebriaeezadeh, Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199197/
https://www.ncbi.nlm.nih.gov/pubmed/25328898
http://dx.doi.org/10.4103/2279-042X.141101
_version_ 1782339871862423552
author Hashemi-Meshkini, Amir
Varmaghani, Mehdi
Yousefi, Mehdi
Yaghoubifard, Saeed
Zekri, Hedieh-Sadat
Nikfar, Shekoufeh
Kebriaeezadeh, Abbas
author_facet Hashemi-Meshkini, Amir
Varmaghani, Mehdi
Yousefi, Mehdi
Yaghoubifard, Saeed
Zekri, Hedieh-Sadat
Nikfar, Shekoufeh
Kebriaeezadeh, Abbas
author_sort Hashemi-Meshkini, Amir
collection PubMed
description OBJECTIVE: Brand-generic scheme was implemented in Iran to improve the competition in the pharmaceutical market. In this study, we aim to assess if this policy had any positive effect on efficiency of Iranian pharmaceutical companies. METHODS: We used data envelopment analysis to evaluate the relative efficiency of pharmaceutical companies during 1999-2008. The Wilcoxon matched-pairs signed-rank and sign tests were used to assess the difference between mean technical efficiency of companies before and after implementation of the new policy. FINDINGS: Although the Wilcoxon matched-pairs signed-rank tests did not show any significant differences in favor of the new policy in terms of both relative and pure (managerial) technical efficiency for included companies (P = 0.079 and 0.07, respectively), but the one-sided sign test indicated that only relative pure (managerial) efficiency has been improved after this policy (P = 0.031). CONCLUSION: The “brand-generic scheme” does not seem to be a successful policy to improve efficiency level and prompt competition in pharmaceutical companies in Iran. To achieve this aim, consideration of infrastructural requirements including transparent and non-discriminating laws and regulations to support competition, the competitive pricing policies, the presence of international companies in the market, and full privatization of companies had to be also deeming by policy makers.
format Online
Article
Text
id pubmed-4199197
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41991972014-10-17 From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies? Hashemi-Meshkini, Amir Varmaghani, Mehdi Yousefi, Mehdi Yaghoubifard, Saeed Zekri, Hedieh-Sadat Nikfar, Shekoufeh Kebriaeezadeh, Abbas J Res Pharm Pract Original Article OBJECTIVE: Brand-generic scheme was implemented in Iran to improve the competition in the pharmaceutical market. In this study, we aim to assess if this policy had any positive effect on efficiency of Iranian pharmaceutical companies. METHODS: We used data envelopment analysis to evaluate the relative efficiency of pharmaceutical companies during 1999-2008. The Wilcoxon matched-pairs signed-rank and sign tests were used to assess the difference between mean technical efficiency of companies before and after implementation of the new policy. FINDINGS: Although the Wilcoxon matched-pairs signed-rank tests did not show any significant differences in favor of the new policy in terms of both relative and pure (managerial) technical efficiency for included companies (P = 0.079 and 0.07, respectively), but the one-sided sign test indicated that only relative pure (managerial) efficiency has been improved after this policy (P = 0.031). CONCLUSION: The “brand-generic scheme” does not seem to be a successful policy to improve efficiency level and prompt competition in pharmaceutical companies in Iran. To achieve this aim, consideration of infrastructural requirements including transparent and non-discriminating laws and regulations to support competition, the competitive pricing policies, the presence of international companies in the market, and full privatization of companies had to be also deeming by policy makers. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4199197/ /pubmed/25328898 http://dx.doi.org/10.4103/2279-042X.141101 Text en Copyright: © Journal of Research in Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hashemi-Meshkini, Amir
Varmaghani, Mehdi
Yousefi, Mehdi
Yaghoubifard, Saeed
Zekri, Hedieh-Sadat
Nikfar, Shekoufeh
Kebriaeezadeh, Abbas
From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
title From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
title_full From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
title_fullStr From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
title_full_unstemmed From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
title_short From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
title_sort from generic scheme to brand-generic scheme: have new policy influenced the efficiency of iranian pharmaceutical companies?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199197/
https://www.ncbi.nlm.nih.gov/pubmed/25328898
http://dx.doi.org/10.4103/2279-042X.141101
work_keys_str_mv AT hashemimeshkiniamir fromgenericschemetobrandgenericschemehavenewpolicyinfluencedtheefficiencyofiranianpharmaceuticalcompanies
AT varmaghanimehdi fromgenericschemetobrandgenericschemehavenewpolicyinfluencedtheefficiencyofiranianpharmaceuticalcompanies
AT yousefimehdi fromgenericschemetobrandgenericschemehavenewpolicyinfluencedtheefficiencyofiranianpharmaceuticalcompanies
AT yaghoubifardsaeed fromgenericschemetobrandgenericschemehavenewpolicyinfluencedtheefficiencyofiranianpharmaceuticalcompanies
AT zekrihediehsadat fromgenericschemetobrandgenericschemehavenewpolicyinfluencedtheefficiencyofiranianpharmaceuticalcompanies
AT nikfarshekoufeh fromgenericschemetobrandgenericschemehavenewpolicyinfluencedtheefficiencyofiranianpharmaceuticalcompanies
AT kebriaeezadehabbas fromgenericschemetobrandgenericschemehavenewpolicyinfluencedtheefficiencyofiranianpharmaceuticalcompanies